CDC grand rounds: The growing threat of multidrug-resistant gonorrhea

Morbidity and Mortality Weekly Report

Volumn 62, Issue 6, 2013, Pages 103-106

  Hook III, Edward W ^a   Shafer, William ^b   Deal, Carolyn ^c   Kirkcaldy, Robert D ^d   Iskander, John ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EMORY UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874323345     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. CDC. Sexually transmitted disease surveillance 2011. Atlanta, GA: US Department of Health and Human Services; 2012. Available at http://www.cdc.gov/std/stats11/surv2011.pdf.
2. Newman LM, Berman SM. Epidemiology of STD disparities in African American communities. Sex Transm Dis 2008;35(12 Suppl):S4-12.
3. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332-6.
4. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12).
5. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55:3538-45.
6. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273-80.
7. Cámara J, Serra J, Ayats, J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67:1858-60.
8. CDC. Update to CDC's sexually transmitted diseases treatment 2010 guidelines: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR 2012;61:590-4.
9. Kunz AN, Begum AA, D'Ambrozio JA, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis 2012;205:1821-9.
10. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64.
11. Dicker LW, Mosure DJ, Steece R, Stone KM. Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2000. Sex Transm Dis 2004;31:259-64.
12. CDC. Volume and type of laboratory testing methods for sexually transmitted diseases in public health laboratories, 2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/std/general/labsurveyreport-2011.pdf.
13. Wong W, Miller S, Rabins C, et al. STD program capacity and preparedness in the United States: results of a national survey, 2009 (Abstract 22048). The 13th Annual Meeting of the National Coalition of STD Directors. Washington, DC, October 27-30, 2009.
14. CDC. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. US Department of Health and Human Services, CDC; 2012. Available at http://www.cdc.gov/std/treatment/ceph-rresponseplanjuly30-2012.pdf.